Crossmark

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Crossref DOI link: https://doi.org/10.1016/j.pulmoe.2020.03.001

Published Online: 2025-03-10

Published Print: 2021-03-30

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Arrobas, A.

Barbosa, M.P.

Rabiais, S.

Vandewalle, B.

Félix, J.
Funding

Funding for this research was provided by:

Novartis Pharma AG
License Information

Version of Record valid from 2021-03-30
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tpul20

Publication History

Received: 2019-02-06

Accepted: 2020-03-02

Published: 2025-03-10